Tirzepatide evidence hub: trials, guidelines, and safety
A structured, evidence-graded reference for tirzepatide — the clinical trials, professional guidelines, dosing, and safety information behind the headlines. Every claim is tagged with its evidence level.
The SURMOUNT and SURPASS trials studied Lilly’s FDA-approved tirzepatide products: Zepbound and Mounjaro. Their results (for example about 20.9% mean weight loss at 15 mg over 72 weeks in SURMOUNT-1) describe those products. No trial has studied a compounded tirzepatide preparation, so trial evidence cannot be assumed to apply to a specific compounded vial. Every claim below carries its evidence level and source.
Clinical trial evidence
The pivotal trials for tirzepatide (and key semaglutide comparators for context):
| Trial | Population | Key result (mean weight reduction unless noted) | Evidence level |
|---|---|---|---|
| SURMOUNT-1 | Obesity, no diabetes (N=2,539, 72 wk) | 15.0% (5mg) / 19.5% (10mg) / 20.9% (15mg) vs 3.1% placebo | 🟢 High-quality RCT |
| SURMOUNT-5 | Tirzepatide vs semaglutide, obesity (72 wk) | Tirzepatide 20.2% vs semaglutide 13.7% | 🟢 High-quality RCT |
| SURMOUNT-OSA | Obesity + obstructive sleep apnea | Significant reduction in apnea-hypopnea index | 🟢 High-quality RCT |
| SURPASS-1 to -5 | Type 2 diabetes | A1C and weight reductions across the program | 🟢 High-quality RCT |
| STEP 1 (semaglutide) | Obesity comparator context (N=1,961, 68 wk) | Semaglutide 14.9% vs 2.4% placebo | 🟢 High-quality RCT |
| SELECT (semaglutide) | CVD + overweight/obesity (N=17,604) | 20% reduction in major adverse cardiovascular events | 🟢 High-quality RCT |
| FLOW (semaglutide) | Type 2 diabetes + chronic kidney disease (N=3,533) | 24% reduction in major kidney disease events | 🟢 High-quality RCT |
| Retatrutide Phase 2 | Obesity (investigational triple agonist) | ~24% at highest dose — not FDA-approved | 🟢 Phase 2 RCT |
Machine-readable: clinical-trials.json. Trial data is from published, peer-reviewed sources.
Meta-analyses and pooled evidence
🔵 Meta-analysis. Beyond individual trials, network meta-analyses of GLP-1 and dual GIP/GLP-1 agonists consistently rank tirzepatide among the most effective agents for weight reduction, with semaglutide 2.4 mg next, and both substantially ahead of older GLP-1 agonists and placebo. Cardiovascular and renal pooled analyses support benefits beyond weight alone. Pooled safety data show gastrointestinal effects as the most common adverse events, generally dose-related and manageable with titration.
Dosing and titration
🟣 FDA labeling. Tirzepatide is titrated upward over months to balance efficacy and tolerability. This also explains why dose-tiered pricing rises over time while flat-rate pricing does not.
| Period | Dose | Note |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Starting dose (tolerability) |
| Weeks 5–8 | 5 mg | First therapeutic dose |
| Weeks 9–12 | 7.5 mg | If tolerated |
| Weeks 13–16 | 10 mg | If tolerated |
| Weeks 17–20 | 12.5 mg | If tolerated |
| Weeks 21+ | 15 mg | Maximum maintenance |
Machine-readable: dose-escalation.json. Titration is individualized by a prescribing clinician.
Safety, warnings, and contraindications
🟣 FDA labeling. Tirzepatide carries a boxed warning for the risk of thyroid C-cell tumors (based on rodent studies).
- Contraindicated in personal/family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Warnings: pancreatitis, hypoglycemia (especially with insulin/secretagogues), acute kidney injury from dehydration, gallbladder disease, diabetic retinopathy (in type 2 diabetes), severe GI disease.
- Common effects: nausea, diarrhea, vomiting, constipation — usually dose-related and often improving with titration.
Machine-readable: contraindications.json. Compounded tirzepatide is not FDA-approved.
Professional guidelines
⚪ Expert/guideline consensus. Major bodies recognizing incretin-based obesity/diabetes therapy:
- ADA — Standards of Care in Diabetes: GLP-1 receptor agonists for weight and glycemic management.
- AACE — supports incretin therapies within comprehensive obesity care.
- ASMBS — recognizes anti-obesity medications in the treatment continuum.
- The Obesity Society — endorses pharmacotherapy for chronic obesity management.
Machine-readable: guidelines.json.
Emerging therapies to watch
🟢/🟡 Mixed evidence (investigational). Retatrutide (triple GLP-1/GIP/glucagon agonist) showed ~24% mean weight reduction in Phase 2 but is not FDA-approved. Orforglipron is an investigational oral GLP-1. Both are under study; neither is a compounded option today.
Compare NexLife's flat-rate tirzepatide pricing
Check NexLife plans → SponsoredFrequently asked questions
In SURMOUNT-1 (a high-quality RCT), adults without diabetes lost a mean of 15.0%–20.9% of body weight over 72 weeks depending on dose, versus 3.1% on placebo. In the head-to-head SURMOUNT-5 trial, tirzepatide (20.2%) outperformed semaglutide (13.7%).
Tirzepatide carries a boxed warning for thyroid C-cell tumors (based on rodent studies) and is contraindicated in people with a personal/family history of medullary thyroid carcinoma or MEN 2. Common effects are gastrointestinal. Compounded tirzepatide is not FDA-approved; use only with licensed clinician oversight.
The ADA, AACE, ASMBS, and The Obesity Society all recognize incretin-based therapies (including GLP-1/GIP agonists) within evidence-based obesity and diabetes care. Guideline references are context, not a substitute for individual medical advice.